Edith L. Graham

Edith L. Graham

Auto-generated profile, based on publicly available information

Edith L. Graham

Department of Neurology, Multiple Sclerosis and Neuroimmunology, Northwestern University, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2021 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
EGEdith L. Graham
Edith L. Graham
JCJeffrey R. Clark
Jeffrey R. Clark
ZOZachary S. Orban
Zachary S. Orban
PLPatrick H. Lim
Patrick H. Lim
ASApril L. Szymanski
April L. Szymanski
IKIgor J. Koralnik
Igor J. Koralnik
Objective: Most SARS‐CoV‐2‐infected individuals never require hospitalization. However, some develop prolonged symptoms. We sought to characterize the spectrum of neurologic manifestations in non‐hospitalized Covid‐19 “long haulers”.Methods: This is a prospective study of the first 100 consecutive patients (50 SARS‐CoV‐2 laboratory‐positive (SARS‐CoV‐2+) and 50 laboratory‐negative (SARS‐CoV‐2‐) individuals) presenting to our Neuro‐Covid‐19 clinic between May and November 2020. Due to early pandemic testing limitations, patients were included if they met Infectious Diseases Society of America symptoms of Covid‐19, were never hospitalized for pneumonia or hypoxemia, and had neurologic symptoms lasting over 6 weeks. We recorded the frequency of neurologic symptoms and analyzed patient‐reported quality of life measures and standardized cognitive assessments.Results: Mean age was 43.2 ± 11.3 years, 70% were female, and 48% were evaluated in televisits. The most frequent comorbidities were depression/anxiety (42%) and autoimmune disease (16%). The main neurologic manifestations were: “brain fog” (81%), headache (68%), numbness/tingling (60%), dysgeusia (59%), anosmia (55%), and myalgias (55%), with only anosmia being more frequent in SARS‐CoV‐2+ than SARS‐CoV‐2‐ patients (37/50 [74%] vs. 18/50 [36%]; p < 0.001). Moreover, 85% also experienced fatigue. There was no correlation between time from disease onset and subjective impression of recovery. Both groups exhibited impaired quality of life in cognitive and fatigue domains. SARS‐CoV‐2+ patients performed worse in attention and working memory cognitive tasks compared to a demographic‐matched US population (T‐score 41.5 [37, 48.25] and 43 [37.5, 48.75], respectively; both p < 0.01).Interpretation: Non‐hospitalized Covid‐19 “long haulers” experience prominent and persistent “brain fog” and fatigue that affect their cognition and quality of life.

24 May 2022 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
SASareen T. Ali
Sareen T. Ali
AKAnthony K. Kang
Anthony K. Kang
TPTulsi R. Patel
Tulsi R. Patel
JCJeffrey R. Clark
Jeffrey R. Clark
GPGina S. Perez‐Giraldo
Gina S. Perez‐Giraldo
IKIgor J. Koralnik
Igor J. Koralnik
Objective: We characterized the evolution of neurologic symptoms and self‐perceived recovery of non‐hospitalized COVID‐19 “long haulers” 6–9 months after their initial Neuro‐COVID‐19 clinic evaluation.Methods: In this follow‐up study on the first 100 patients, 50 SARS‐CoV‐2 laboratory‐positive (SARS‐CoV‐2+), and 50 laboratory‐negative (SARS‐CoV‐2−), evaluated at our Neuro‐COVID‐19 clinic between May and November 2020, patients completed phone questionnaires on their neurologic symptoms, subjective impression of recovery and quality of life.Results: Of 52 patients who completed the study (27 SARS‐CoV‐2+, 25 SARS‐CoV‐2−) a median 14.8 (range 11–18) months after symptom onset, mean age was 42.8 years, 73% were female, and 77% were vaccinated for SARS‐CoV‐2. Overall, there was no significant change in the frequency of most neurologic symptoms between first and follow‐up evaluations, including “brain fog” (81 vs. 71%), numbness/tingling (69 vs. 65%), headache (67 vs. 54%), dizziness (50 vs. 54%), blurred vision (34 vs. 44%), tinnitus (33 vs. 42%), and fatigue (87 vs. 81%). However, dysgeusia and anosmia decreased overall (63 vs. 27%, 58 vs. 21%, both p < 0.001). Conversely, heart rate and blood pressure variation (35 vs. 56%, p = 0.01) and gastrointestinal symptoms (27 vs. 48%, p = 0.04) increased at follow‐up. Patients reported improvements in their recovery, cognitive function, and fatigue, but quality of life measures remained lower than the US normative population (p < 0.001). SARS‐CoV‐2 vaccination did not have a positive or detrimental impact on cognitive function or fatigue.Interpretation: Non‐hospitalized COVID‐19 “long haulers” continue to experience neurologic symptoms, fatigue, and compromised quality of life 14.8 months after initial infection.

19 April 2023 in Annals of Neurology
Verified
Journal Article
Open access
GGGina S. Perez Giraldo
Gina S. Perez Giraldo
SASareen T. Ali
Sareen T. Ali
AKAnthony K. Kang
Anthony K. Kang
TPTulsi R. Patel
Tulsi R. Patel
SBShreya Budhiraja
Shreya Budhiraja
IKIgor J. Koralnik
Igor J. Koralnik
Objective: To characterize neurologic manifestations in post‐hospitalization Neuro‐PASC (PNP) and non‐hospitalized Neuro‐PASC (NNP) patients.Methods: Prospective study of the first 100 consecutive PNP and 500 NNP patients evaluated at a Neuro‐COVID‐19 clinic between 5/2020 and 8/2021.Results: PNP were older than NNP patients (mean 53.9 vs 44.9 y; p < 0.0001) with a higher prevalence of pre‐existing comorbidities. An average 6.8 months from onset, the main neurologic symptoms were “brain fog” (81.2%), headache (70.3%), and dizziness (49.5%) with only anosmia, dysgeusia and myalgias being more frequent in the NNP compared to the PNP group (59 vs 39%, 57.6 vs 39% and 50.4 vs 33%, all p < 0.003). Moreover, 85.8% of patients experienced fatigue. PNP more frequently had an abnormal neurologic exam than NNP patients (62.2 vs 37%, p < 0.0001). Both groups had impaired quality of life in cognitive, fatigue, sleep, anxiety, and depression domains. PNP patients performed worse on processing speed, attention, and working memory tasks than NNP patients (T‐score 41.5 vs 55, 42.5 vs 47 and 45.5 vs 49, all p < 0.001) and a US normative population. NNP patients had lower results in attention task only. Subjective impression of cognitive ability correlated with cognitive test results in NNP but not in PNP patients.Interpretation: PNP and NNP patients both experience persistent neurologic symptoms affecting their quality of life. However, they harbor significant differences in demographics, comorbidities, neurologic symptoms and findings, as well as pattern of cognitive dysfunction. Such differences suggest distinct etiologies of Neuro‐PASC in these populations warranting targeted interventions. ANN NEUROL 2023;94:146–159

1 January 2023 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
ABArchit Bharathwaj Baskaran
Archit Bharathwaj Baskaran
EGElena Grebenciucova
Elena Grebenciucova
TSThomas Shoemaker
Thomas Shoemaker
EGEdith L Graham
Edith L Graham
Baskaran AB, et al. J Clin Neurol. 2023 May;19(3):217-229. https://doi.org/10.3988/jcn.2022.0208

21 July 2022 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
EGEdith L. Graham
Edith L. Graham
IKIgor J. Koralnik
Igor J. Koralnik
ELEric M. Liotta
Eric M. Liotta

9 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
LVLavanya Visvabharathy
Lavanya Visvabharathy
BHBarbara A. Hanson
Barbara A. Hanson
ZOZachary S. Orban
Zachary S. Orban
PLPatrick H. Lim
Patrick H. Lim
NPNicole M. Palacio
Nicole M. Palacio
RJRishi Jain
Rishi Jain
Many people experiencing long COVID syndrome, or post-acute sequelae of SARS-CoV-2 infection (PASC), suffer from debilitating neurologic symptoms (Neuro-PASC). However, whether virus-specific adaptive immunity is affected in Neuro-PASC patients remains poorly understood. We report that Neuro-PASC patients exhibit distinct immunological signatures composed of elevated humoral and cellular responses toward SARS-CoV-2 Nucleocapsid protein at an average of 6 months post-infection compared to healthy COVID convalescents. Neuro-PASC patients also had enhanced virus-specific production of IL-6 from and diminished activation of CD8 + T cells. Furthermore, the severity of cognitive deficits or quality of life disturbances in Neuro-PASC patients were associated with a reduced diversity of effector molecule expression in T cells but elevated IFN-γ production to the C-terminal domain of Nucleocapsid protein. Proteomics analysis showed enhanced plasma immunoregulatory proteins and reduced pro-inflammatory and antiviral response proteins in Neuro-PASC patients compared with healthy COVID convalescents, which were also correlated with worse neurocognitive dysfunction. These data provide new insight into the pathogenesis of long COVID syndrome and a framework for the rational design of predictive biomarkers and therapeutic interventions. One Sentence Summary: Adaptive immunity is altered in patients with neurologic manifestations of long COVID.